4//SEC Filing
Hora Maninder 4
Accession 0001209191-18-047240
CIK 0000906709other
Filed
Aug 15, 8:00 PM ET
Accepted
Aug 16, 9:44 PM ET
Size
11.2 KB
Accession
0001209191-18-047240
Insider Transaction Report
Form 4
Hora Maninder
SVP Pharma Dev and Mfg
Transactions
- Disposition to Issuer
Common Stock
2018-08-16$58.40/sh−5,946$347,246→ 85,723 total - Award
Common Stock
2018-08-15+15,000→ 91,669 total - Award
Stock Option
2018-08-15+37,500→ 37,500 totalExercise: $56.90Exp: 2025-12-14→ Common Stock (37,500 underlying)
Footnotes (7)
- [F1]Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.
- [F2]This number includes 6,968 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
- [F3]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F4]This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- [F5]These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017).
- [F6]These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181.
- [F7]This stock option vests on a monthly pro-rata basis over a period of four years from the grant date.
Documents
Issuer
NEKTAR THERAPEUTICS
CIK 0000906709
Entity typeother
Related Parties
1- filerCIK 0001443159
Filing Metadata
- Form type
- 4
- Filed
- Aug 15, 8:00 PM ET
- Accepted
- Aug 16, 9:44 PM ET
- Size
- 11.2 KB